最新消息

News
漢康生技 HCB301 臨床進展說明
漢康生技 HCB301 臨床進展說明:與 FDA 共同重視病患安全,積極優化臨床方案,持續展現創新免疫療法潛力 […]
11 月 18, 2026
Read more
漢康生技攜手高醫簽署合作備忘錄 深化癌症臨床研究合作 HanchorBio and Kaohsiung Medical University Hospital Sign MOU to Strengthen Cancer Clinical Research Collaboration
HanchorBio announced the signing of a Memorandum of Understanding (MOU) with Kaohsiung Medical University Hospital (KMUH). The collaboration combines HanchorBio's expertise in innovative drug development and clinical development with KMUH's clinical and research expertise in gastrointestinal oncology to explore potential opportunities for future clinical research. Both parties aim to generate additional scientific evidence in cancer research through clinical studies, while maintaining rigorous standards of patient safety, medical ethics, and regulatory compliance.
11 月 05, 2026
Read more
漢康生技 HCB303 採差異化 TIGIT-Fc 策略 繼美國 FDA 後再獲台灣 TFDA 核准臨床試驗 Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance
HanchorBio announced that its wholly owned subsidiary, FBD Biologics Limited, has received approval from the Taiwan Food and Drug Administration (TFDA) for the Investigational New Drug (IND) application for HCB303, a next-generation trispecific fusion protein featuring a differentiated TIGIT-Fc ligand-trap strategy.
10 月 30, 2026
Read more
漢康生技攜手 Aston Sci 展開策略合作 結合癌症疫苗與次世代免疫療法,探索創新聯合治療潛力 HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
HanchorBio and Aston Sci today announced a strategic research collaboration to evaluate novel combination therapies joining HanchorBio's HCB101 macrophage-directed immunotherapy with Aston Sci's therapeutic cancer vaccine candidates.
10 月 22, 2026
Read more
漢康生技召開科學顧問委員會議 HCB101 臨床進展與 FDA 共識支持邁向全球註冊性臨床開發 HanchorBio Advances HCB101 Toward Global Registrational Development Following SAB Review and FDA Alignment
HanchorBio announced outcomes from its latest Scientific Advisory Board (SAB) meeting. Highlights included significant clinical progress for its lead asset, HCB101; alignment with the U.S. FDA on a registrational pathway in second-line gastric/ gastroesophageal junction (GC/GEJ) cancer; and continued expansion of the company’s research pipeline across oncology and immune-mediated diseases.
10 月 19, 2026
Read more
漢康生技擴大 HCB101 於台灣大腸直腸癌臨床開發 二線治療初步數據顯示 ORR 達 50%、DCR 達 100% HanchorBio Expands HCB101 Colorectal Cancer Program in Taiwan as Early 2L CRC Data Show 50% ORR and 100% DCR
HanchorBio today announced that the first patient in Taiwan has been dosed in the colorectal cancer (CRC)-specific cohort of its global Phase 1b/2a HCB101-201 study (NCT06771622), expanding the Company’s global development program in second-line metastatic CRC.
10 月 14, 2026
Read more
漢康-KY向TFDA提交 HCB303 IND 申請 推進三特異性免疫療法全球臨床開發 HanchorBio Advances HCB303 Global Clinical Development with Taiwan TFDA IND Submission Following US FDA Clearance
HanchorBio announced the submission of an Investigational New Drug (IND) to the Taiwan Food and Drug Administration (TFDA) for HCB303.
10 月 08, 2026
Read more
漢康-KY宣布 HCB303 IND 獲美國 FDA 同意 新一代三特異性免疫療法邁入臨床開發 HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy
HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303. The clearance enables HanchorBio to initiate its Phase 1 first-in-human clinical trial.
10 月 03, 2026
Read more
漢康-KY第二屆技術研發日揭示全球成長策略與多元產品線布局 HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day
HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.
9 月 23, 2026
Read more
漢康生技五項臨床研究入選 CSCO 2026 HanchorBio to Present Five Clinical Abstracts at CSCO 2026
HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).
9 月 18, 2026
Read more